Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sovilnesib in Advanced Solid Tumors
NCT06084416Phase 1Recruiting
- Sponsor
- Volastra Therapeutics
- Start
- Apr 2024
- Primary completion
- Nov 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of sovilnesib in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal carcinoma (PPC) (4 arms), sponsored by Volastra Therapeutics. Primary endpoints: Recommended Phase 2 Dose at 24 months, Serious Adverse Events at 24 months and 4 more. Started Apr 2024; status: recruiting.
02
Drugs
sovilnesib
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal carcinoma (PPC)
Beyond the preview
Go deeper on NCT06084416.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06084416.